

1 **Identifying the target population for primary Respiratory Syncytial Virus two-step**  
2 **prevention in infants:**

3 **Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN)**

4  
5 *Marine Jourdain<sup>1</sup>, Mehdi Benchaib<sup>2</sup>, Dominique Ploin<sup>3,4</sup>, Yves Giller<sup>3</sup>, Etienne Javouhey<sup>3</sup>,*  
6 *Côme Horvat<sup>3</sup>, Mona Massoud<sup>4</sup>, Marine Butin<sup>5</sup>, Olivier Claris<sup>5</sup>, Bruno Lina<sup>1,4</sup>, on behalf of*  
7 *the VRS study group in Lyon, Jean-Sebastien Casalegno<sup>1,4</sup>*

8 1 Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Centre de Biologie Nord, Institut des  
9 Agents Infectieux, Laboratoire de Virologie, Lyon, France;

10 2 Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de Médecine et de la  
11 Reproduction, Bron, France,

12 3 Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de Réanimation Pédiatrique  
13 et d'Accueil des Urgences, Bron, France,

14 4 CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon,  
15 Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale  
16 Supérieure de Lyon, F-69007, Lyon, FR.

17 5 Hospices Civils de Lyon, Service de Gynécologie-Obstétrique, Hôpital Femme-Mère-  
18 Enfant, Bron, France ;

19 6 Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de Néonatalogie et de  
20 Réanimation Néonatale, Bron, France

21  
22  
23  
24  
25  
26 Running title: Building a score to predict RSV hospitalisation in infants

27 Keywords: RSV; Bronchiolitis; Predictive Score; Lower Respiratory Tract Infection, Primary  
28 prevention, monoclonal antibody, public health, vaccines

29 Corresponding author: Jean-Sebastien CASALEGNO

30 CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm,

31 U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon; 7 rue

32 Guillaume Paradin, 69 372 Lyon Cedex 08

33 tel: +33478778621 mail: [jean-sebastien.casalegno@chu-lyon.fr](mailto:jean-sebastien.casalegno@chu-lyon.fr)

34

## 35 **Summary**

### 36 **Background:**

37 Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection related  
38 hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with  
39 no known risk factors. An efficient RSVh prevention program should address both mothers  
40 and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This  
41 study aimed at identifying the target population for these two interventions.

### 42 **Methods:**

43 Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were  
44 enrolled from the *Hospices Civils de Lyon* birth cohort (2014 to 2018). Clinical variables  
45 related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were  
46 used for descriptive epidemiology, multivariate logistic regression, and predictive score  
47 development.

### 48 **Findings:**

49 Overall, 616 cases of RSVh in 45 648 infants were identified. Being born before the epidemic  
50 season, prematurity, and multiparity were independent predictors of RSVh. Infants born in  
51 January or June to August with prematurity and multiparity, and those born in September or  
52 December with only one other risk factor (prematurity or multiparity) were identified as  
53 moderate-risk, identifying the mothers as candidates for a first level NPI prevention program.  
54 Infants born in September or December with prematurity and multiparity, and those born in  
55 October or November were identified as high-risk, identifying the mothers and infants as  
56 candidates for a second level (NPI and PI) intervention.

### 57 **Interpretation:**

58 It is possible to determine predictors of RSVh at birth, allowing to enrol early the target  
59 population in a two-level RSV prevention intervention.

### 60 **Funding**

61 None.

## 62 **Research in context**

### 63 **Evidence before this study**

64 In infants, the global burden of disease caused by the respiratory syncytial virus (RSV) is  
65 increasingly recognised. Nowadays the prevention programs are limited to the only licensed  
66 drug, Palivizumab, a humanised monoclonal antibody that shows some benefit in preventing  
67 RSV in high-risk infants. With the recent encouraging progress obtained using a maternal  
68 vaccine candidate and long half-life monoclonal antibodies administered to newborns, as well  
69 as the impact of Covid-19 non-pharmaceutical interventions on the RSV epidemic, there is an  
70 urgent need to revisit this prevention paradigm from a much broader perspective.

### 71 **Added value of this study**

72 Using a hospital birth cohort (NOHAN strategy) split into a training and a testing dataset, we  
73 were able to determine strong maternal and newborn predictors for the risk of RSV  
74 hospitalisation. Month of birth, multiparity, and prematurity were sufficient to accurately  
75 identify low-, moderate-, and high-risk groups in the validating cohort.

### 76 **Implications of all the available evidence**

77 Using the NOHAN strategy, future parents could be enrolled early during pregnancy follow-  
78 up in a health-related behaviour change program and then be proposed a vaccine boost for the  
79 pregnant women or neutralizing monoclonal antibodies for the newborns. The thresholds for  
80 triggering each intervention can be adjusted to the local epidemiology, the resources  
81 available, and the evolving evidence concerning the cost-efficiency of the future  
82 interventions. Stakeholders, healthcare professionals and policy makers must acknowledge  
83 this opportunity when designing the future of RSV prevention programs.

84

## 85 **Introduction**

86 Respiratory syncytial virus (RSV) infection is the predominant cause of lower respiratory  
87 tract infection (LRTI) in infants.<sup>1,2</sup> In developed countries, RSV represents the leading cause  
88 of hospitalisation during the first year of life,<sup>3</sup> with up to 3% of all infants hospitalised every  
89 year.<sup>4</sup> Severe cases are more frequent in infants younger than 3 months<sup>5</sup> and in infants with  
90 known risk factors such as prematurity, lung or heart diseases, and immunodeficiency.<sup>6</sup>  
91 However, most infants hospitalised with RSV LRTI have no known risk factors.<sup>2,7,8</sup>  
92 Although RSV is now recognised as a major health burden worldwide, preventive approaches  
93 remain limited. Non-Pharmaceutical Interventions (NPI) such as hand hygiene, breastfeeding,  
94 and avoiding exposure to smoke or persons with acute respiratory illness are effective in  
95 reducing the risk of infection with respiratory viruses in infants.<sup>9,10</sup> The implementation of  
96 NPI on a large scale during the COVID-19 pandemic, which strongly reduced the RSV  
97 epidemic,<sup>11</sup> advocates for a stronger implementation of NPI. Pharmaceutical Intervention (PI)  
98 is currently limited to the only licensed drug, Palivizumab, a humanised monoclonal antibody  
99 that shows some benefit in preventing RSV in high risk infants.<sup>12</sup> More recently, encouraging  
100 progress was made using a fusion protein nanoparticle vaccine administered to pregnant  
101 women<sup>13</sup> and long half-life monoclonal antibodies administered to newborns.<sup>14</sup> Considering  
102 the numerous PIs for RSV prevention currently being evaluated in clinical trials, there is a  
103 reasonable hope that in coming years, PI will be broadly recommended to the general  
104 population.<sup>15</sup>  
105 Nevertheless, successful implementation of the future prevention programs largely relies on  
106 their capacity to target the mothers of infants with the higher risk. Recently, it has been  
107 reported that prophylaxis regimens, adjusted for regional variations in terms of RSV  
108 seasonality, may improve protection compared to the implementation of nationally  
109 recommended regimens.<sup>15,16</sup>

110 Predictive models can help adjust the preventive action to the target population.<sup>17</sup> Regarding  
111 the risk of RSV-associated hospitalisation (RSVh), most of the published predictive models  
112 have focused on high risk preterm infants.<sup>18–22</sup> Only Houben *et al* proposed a simple  
113 prediction rule that can identify infants at risk of RSV LRTI, but the cohort was limited in  
114 size and the score designed only for clinical use.<sup>23</sup>  
115 The Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN) strategy  
116 proposed herein aimed to adjust multi-level mother-infant interventions according to the risk  
117 of RSVh at the general population level. The cut-off values can be adapted to balance the  
118 resources available and the effectiveness of the preventive approach.

119

## 120 **Methods**

### 121 **Data sources**

122 Demographic and laboratory data were collected retrospectively. First, the administrative  
123 registry of all infants born in the University Hospitals of Lyon (*Hospices Civils de Lyon*,  
124 HCL) was used. Stillborn children or those living outside the region were excluded. This  
125 database includes the following variables of interest: gender (male/female), month of birth,  
126 gestational age (WG), maternal parity (primiparity/multiparity), plurality (single/multiple  
127 gestation), childbirth type (vaginal birth/caesarean section), birth weight, and geographical  
128 living area (postcode). Patients with at least one missing data for any studied variable were  
129 excluded. The virology laboratory database was then used to identify, among all infants born  
130 in the HCL and hospitalised during the RSV season with acute respiratory infection  
131 symptoms, those with a respiratory sample positive for RSV.<sup>24</sup>

132 Cases were defined as a new admission, during the first 6 months of life, to one of the  
133 conventional paediatric hospital departments of the HCL with an RSV positive sample during  
134 hospital stay. This 6-month follow-up period is in line with the preventive approaches  
135 proposed herein (NPI, maternal vaccination program, monoclonal antibodies administered at

136 birth) which are mostly protective over the first 6 months of life.<sup>17</sup> Presumed nosocomial  
137 cases (i.e. cases observed during the birth stay) were not excluded considering that only few  
138 cases were expected and that transmission from the community (mother, siblings, family)  
139 could not be ruled out.

140

#### 141 **Variable and categorical construction**

142 A term delivery was defined as a baby born > 37 weeks of gestation (WG) measured in weeks  
143 of amenorrhoea (WA). Moderate and very preterm deliveries were defined as a baby born  $\geq$   
144 32 WG and  $\leq$  37 WG and a baby born  $\leq$  32 WG, respectively.

145 Birth weight was categorised as either low or high when the value was outside 2 standard  
146 deviations of the weight cohort distribution per WG. Month of birth was categorised into four  
147 groups with increased incidence of RSVh during the first 6 months of life.

148 The choice to aggregate these two variables was made to match the categories used in  
149 guidelines and clinical practice and to further facilitate the implementation of the.<sup>25</sup>

150

#### 151 **Cohort construction**

152 Overall, 45 648 infants were included in the study (2014 to 2018) from a catchment area of  
153 1,370,678 inhabitants using public hospital registry data from the HCL (Figure 1).<sup>26</sup> To ensure  
154 the stability of the score, the population studied was divided into three cohorts. The validating  
155 cohort was defined as the 2018 birth cohort (n=8 709 infants born between January 2018 and  
156 December 2018). The remaining cohort (2014 to 2017) was then randomly divided, with  
157 equal-sized month of birth proportion, into a training cohort (70% of the remaining cohort, n=  
158 25 858) and a testing cohort (30% of the remaining cohort, n=11 081). The validating cohort  
159 was exposed to the 2018/2019 RSV season which was similar to the previous epidemics<sup>27</sup>  
160 (Table 1).

161

## 162 **Identification of predictors of interest and predictive score generation**

163 To identify potential independent maternal RSVh predictors, all variables of the training  
164 cohort were entered into a multivariate backwards stepwise logistic regression model to  
165 remove predictors that did not significantly improve the fit of the logistic regression model  
166 (based on a p-value of 0•10). The odds ratio (OR) values obtained from the final model were  
167 rounded to the nearest integer and used to determine the score. The model was adjusted with  
168 the year of birth and the hospital of birth (Table 2).

169

## 170 **Estimation of the model's performance and variance**

171 To evaluate the optimism-corrected performance values, the real-life model's performance  
172 was quantified using the area under the receiver operating characteristic curve (AUROC)  
173 (with 95% confidence interval) and the Brier score in the testing and validating cohorts. A k-  
174 fold (with k=4) cross validation approach was used to estimate the model's variance on the  
175 training cohort. The distribution of month of birth was preserved in the split training sets  
176 obtained using the k-fold cross validation. The validating cohort corresponds to a new set of  
177 infants exposed to a new RSV epidemic and was used as an external control.

178 In the absence of any similar predictive model but based on references from research on other  
179 medical predictive models, and given the potential cost-effectiveness of the preventive  
180 program, an AUROCC  $\geq 0\cdot70$  was considered as evidence for good discrimination.<sup>28,29</sup> A test  
181 was considered significant when p value was lower than 0•05.

182

## 183 **Determining the cut-off values of the two-level preventive program**

184 The optimal cut-off value for the first level of intervention (NPI alone) was defined *a priori*  
185 with minimal sensitivity and specificity values of 80 % and 20%, respectively. This cut-off  
186 assumed a lower cost and effectiveness for NPI compared to PI. However, an NPI preventive  
187 program may not be maintained all year-round if the perceived risk is too low. This



188 assumption was informed based on the results showing that the application of NPI measures  
189 by French parents decreased over time during the COVID-19 crisis (CoviPrev survey).<sup>30</sup>  
190 The optimal cut-off value for the second level of intervention (NPI and PI) was defined *a*  
191 *priori* with a minimal specificity value of 80%. This cut-off assumed a higher cost and  
192 effectiveness for PI that would be then more suitable for a timely seasonal administration than  
193 a year-round administration.<sup>31</sup>

194

### 195 **Statistical analyses**

196 Statistical analyses were performed using R software version 4.1.0 with the following  
197 packages (ggplot2; reshape2; doBy; caret; scoring, pROC). The caret library was used for  
198 data splitting. For the comparison of cohorts, p values were derived using the chi-squared test  
199 for qualitative variables and the Student's t-test or ANOVA tests for quantitative variables.

200

### 201 **Ethics**

202 Parents of infants for whom hospitalisation data were used were informed of the study (aim of  
203 the study, use of anonymised data, right to refuse participation) by postal mail. After this first  
204 contact, data were anonymised. Parents of infants for whom hospitalisation data were used  
205 were informed of the study (aim of the study, use of anonymised data, right to refuse  
206 participation) by postal mail. After this first contact, data were anonymised. Authorisation  
207 from Scientific and Ethical Committee of Hospices Civils de Lyon (Comité Scientifique et  
208 Éthique des Hospices Civils de LYON CSE-HCL – IRB 00013204; Pr Cyrille Confavreux)  
209 was obtained on 28/09/2021.

210

### 211 **Role of the funding source**

212 There was no funding source for this study. The corresponding author had full access to all  
213 the data in the study and had the final responsibility for the decision to submit for publication.

214

215

## 216 **Results**

### 217 **Characteristics of the training, testing, and validating cohorts**

218 Several patients were missing data for gestational age and were excluded (572/46 220). The  
219 population studied comprised 45 648 infants, 50•7% (23 140) were boys, 16•1% (7 354) were  
220 born preterm ( $\leq 37$  WG), 5•8% (2 641) from multiple births, 20•8% (9 497) were born by  
221 caesarean section, and 43•7% (19 933) from multiparous mothers. The median (Interquartile  
222 Range [IQR]) birth weight was 3 207 [2 920 -3 580] g. Among them, 616 were hospitalised in  
223 their first 6 months of life with a laboratory-confirmed RSV infection, 53•7% (331) were  
224 boys, 22•8% (140) were born preterm ( $\leq 37$  WG), 7•3% (45) from multiple births, and 73•4%  
225 (452) from multiparous mothers (Table 1). Among all cases, 0•8% (5) were suspected to be  
226 nosocomial. The characteristics of the testing and training cohorts did not significantly differ.  
227 The validating cohort did not significantly differ in terms of mean WG and birth weight when  
228 compared to the testing and training cohorts. Significant differences in the frequencies of  
229 month of birth, parity, gestation type, and childbirth type were observed between the  
230 validating cohort and the testing and training cohorts (Table 1).

231

### 232 **Month of birth categorisation in the population studied**

233 Month of birth was categorised into four groups with increased incidence of RSVh during the  
234 first 6 months of life. In the population studied 95•1% (586/616) of the cases were detected  
235 from November to February with a peak during December (Figure 2). Mean ( $\pm$  Standard  
236 Deviation SD) age at the time of hospitalisation was 2•1 ( $\pm 1•4$ ) months.

237 Incidence was 13•5 infants hospitalised in the first 6 months of life per 1000 infants (95%  
238 Confidence Interval (CI) [12•0;15•0]). The incidence of RSVh in the first 6 months of life  
239 was higher for those born just before the seasonal epidemic, from October to November (41•3

240 cases per 1000 infants (95% CI [37•0;46•0]) compared to those born in September and  
241 December (23•0 cases per 1000 infants (95% CI [20•0;27•0]), as well as to those born in  
242 January and June to August (7•53 cases per 1000 infants (95% CI [6•0;9•0]), and those born  
243 February to May (0•81 cases per 1000 infants (95% CI [0•0;1•0]); Figure 2).

244 In the model analysis, the month of birth was aggregated into these four groups of respective  
245 increased RSVh incidence. The choice to aggregate this variable was done to facilitate the  
246 implementation of the score in the patient and healthcare community in the context of  
247 pregnancy.

248

#### 249 **Maternal predictors of interest associated with increased risk of RSVh (training cohort)**

250 The multivariate logistic regression analysis in the training cohort retrieved three variables  
251 significantly associated with hospitalisation: month of birth, gestational age, and parity.  
252 Considering the month of birth, being born during October and November was associated  
253 with the highest risk of RSVh (OR 46•35, 95% CI [24•40;102•73],  $p < 0•001$ ). Considering  
254 the gestational age, being born  $\square$  32 WG was associated with a higher risk of RSVh (OR  
255 3•26, 95% CI [1•80;5•52],  $p < 0•001$ ). Considering parity, multiparity was associated with a  
256 higher risk of RSVh (OR 3.89, 95% CI [3•07; 4•97],  $p < 0•001$ ; Table 2). These variables,  
257 along with the year of birth and the hospital of birth, were retained in the final predictive  
258 model and used for the score construction.

259

#### 260 **Performance of the RSVh predictive score in the testing and validating cohorts**

261 The final score value ranged from 0 to 53. The mean ( $\pm$  SD) score was 16•98 ( $\pm$  16•42) in the  
262 testing cohort and 18•41 ( $\pm$  19•64) in the validating cohort (external control).

263 The k-fold validation approach used in the training cohort to estimate the model's variance  
264 found a mean AUROC value of 0•791 (95% CI [0•788; 0•793]) for the four split training

265 cohorts compared with a mean AUROC value of 0•821 (95% CI: [0•791; 0•850]) for the  
266 validating cohort. The overlap between the two confidence intervals indicates a low variance.  
267 The Hosmer-Lemehow chi-squared test used to assess the goodness of fit (p value <0•001)  
268 and the Brier score measured (value = 0•0135) in the validating cohort both indicated a good  
269 performance of the predictive model.

270

### 271 **Identifying the target population for the two-level maternal-infant preventive program**

272 The optimal cut-off values of the RSVh predictive score for the first and second levels of  
273 intervention were 14 and 28, respectively. The maternal population with an RSVh predictive  
274 score below the first cut-off value (14) of intervention was defined as a low-risk group (Table  
275 3). It encompasses all the mothers giving birth during the months of February to May and the  
276 deliveries occurring during the months of January or June to August with no more than one  
277 risk factor (prematurity or multiparity).

278 The maternal population with an RSVh predictive score above the first cut-off value (> 14)  
279 and below the second cut-off value (< 28) of intervention was defined as a moderate-risk  
280 group. It encompasses the deliveries occurring during the months of January or June to  
281 August with prematurity and multiparity and the deliveries in September or December with  
282 only one other risk factor (prematurity or multiparity).

283 The maternal population with an RSVh predictive score above the second cut-off value (> 28)  
284 was defined as a high-risk group. It encompasses the deliveries in September or December  
285 with prematurity and multiparity and all deliveries in October or November (Table 3).

286 When applied to the validating cohort, the predictive score identified 53% of infants as low-  
287 risk (incidence 1•72 cases /1000 infants), 32% of infants as moderate-risk (incidence  
288 18•92/1000 infants), and 15% of infants as high-risk (incidence 46•28/1000 infants; Table 3).

289

## 290 **Discussion**

291 In the present study, an original but simple approach was used to identify the target  
292 population for a two-level preventive mother-infant intervention program based on maternal  
293 and newborn risk factors.

294 The clinical predictors identified herein were already described in previous reports.<sup>19–21</sup>  
295 Month of birth is by far the strongest predictor of RSVh in the general birth cohort. This  
296 finding is consistent with numerous previous observations reporting that infants born before  
297 the RSV peak month have the highest RSVh admission rates.<sup>33</sup> Prematurity under 37 WG and  
298 multiparity were also previously associated with increased RSVh risk.<sup>34,35</sup>

299 The present approach differs from other RSVh prediction models.<sup>19–22</sup> The novelty herein is  
300 the use of RSVh risk factors that can be identified early in the pregnancy (month of birth and  
301 multiparity) or at the infant's birth (WG). It allows the inclusion of target mothers and then  
302 infants in a prevention program tailored to the infant's risk of RSVh. The first level entails a  
303 reinforced behaviour change program (BCP) to promote good hygiene practices (hand  
304 hygiene, breastfeeding, avoiding exposure to smoke and persons with acute respiratory  
305 illness) and education on bronchiolitis. The second level is a pharmaceutical prevention  
306 program that will integrate future licensed preventive drug interventions. These BCP and PI  
307 can be introduced early during pregnancy follow-up so that the different healthcare workers  
308 involved in the pregnancy, childbirth, and postnatal periods can repeatedly promote them to  
309 the target population.

310 A major strength of this study was that all the diagnoses were PCR-confirmed, with only  
311 minor missing values. Indeed, identifying cases based on diagnosis codes, such as admissions  
312 for bronchiolitis, is neither fully specific nor sensitive. On one hand, bronchiolitis can be  
313 caused by other respiratory viruses such as rhinoviruses, metapneumoviruses, and  
314 influenzaviruses.<sup>36</sup> On the other hand, RSV admissions could be related to disease codes other  
315 than bronchiolitis (sepsis, acute otitis). According to the hospital's local protocol, all infants  
316 below the age of 1 year old hospitalised with acute respiratory infection, are tested for RSV

317 during the RSV epidemic season.<sup>24</sup> A sensitivity analysis performed over one RSV season  
318 (2016/2017) showed that 83•4% of all hospitalisations for bronchiolitis were due to RSV  
319 (PCR-confirmed), while 11•5% were related to other viruses (5% did not have any sample  
320 tested)<sup>37</sup>. The second major strength of this work is that a complete case analysis was  
321 performed, as there was only a small proportion of infants excluded for missing data. In  
322 addition, dividing the population studied into three cohorts allowed a robust estimation of the  
323 score's performance.

324 There are, however, some limitations to this work. First, the cost-effectiveness of the future  
325 licensed preventive treatments remains to be determined. One consequence of the COVID-19  
326 crisis may be a better integration and promotion of NPI in the prevention of viral respiratory  
327 diseases. Although more costly, the future drugs in development will likely represent a more  
328 efficient preventive approach if dedicated to high-risk infants. Therefore, this two-step  
329 strategy is likely to be considered in the near future. Another limitation is that some known  
330 risk factors (exposure to smoke, parent's education level, mother's age)<sup>38</sup> were not present in  
331 the database and therefore not tested in the model. Palivuzimab use was also not measured in  
332 this study. According to the French guidelines, Palivuzimab is recommended for premature  
333 babies born before 29 WG or born before 32 WG with risk factors. This did not represent  
334 more than 2% of the present birth cohort. Given that extremely premature infants are a small  
335 subgroup of the general population, and that extreme prematurity was still a higher risk factor  
336 than preterm and term births, it was assumed that the general model was not significantly  
337 affected by the use of Palivuzimab.

338 Using a hospital birth cohort, the NOHAN strategy allowed to determine strong maternal and  
339 newborn predictors of RSVh risk. By using this strategy, future parents could be enrolled  
340 early during pregnancy follow-up in a health-related BCP. The pregnant women could then be  
341 proposed a vaccine boost, or neutralizing monoclonal antibodies could be administered to the  
342 newborns. As demonstrated herein, the thresholds for triggering each level of intervention can

343 be adjusted to the local epidemiology, the resources available, and the evolving evidence  
344 concerning the cost-efficiency of the future interventions. Stakeholders, healthcare  
345 professionals and policy makers, should acknowledge this opportunity when designing the  
346 future of RSV prevention programs.

347

348

349

350 **Table 1. Demographic and clinical characteristics of the training, testing, and validating**  
 351 **cohorts.**  
 352

	<b>Training Cohort 2014-2017 N=25 858</b>	<b>Testing Cohort 2014-2017 N=11 081</b>	<b>p value</b>	<b>Validating Cohort 2018 N=8 709</b>	<b>p value</b>
<b>Gender, n (%)</b>					
Male	13 159 (50•9)	5 631 (50•8)	0•90	4 350 (50•0)	0•30
<b>Month of birth, n (%)</b>					
January	2 196 (8•5)	959 (8•7)	0•36	771 (8•9)	<0•0001
February	1 935 (7•5)	841 (7•6)		664 (7•6)	
March	2 152 (8•3)	865 (7•8)		708 (8•1)	
April	2 036 (7•8)	900 (8•1)		753 (8•7)	
May	2 268 (8•8)	913 (8•2)		753 (8•7)	
June	2 155 (8•3)	934 (8•4)		814 (9•4)	
July	2 209 (8•5)	995 (9•0)		821 (9•4)	
August	2 201 (8•5)	922 (8•3)		822 (9•5)	
September	2 120 (8•2)	962 (8•7)		793 (9•1)	
October	2 252 (8•7)	933 (8•4)		633 (7•3)	
November	2 208 (8•5)	920 (8•3)		608 (7•0)	
December	2 126 (8•2)	937 (8•5)		569 (6•5)	
<b>Weeks of gestation, n (%)</b>					
Median (IQR**)	39 [38-40]	39 [38-40]	0•54	39 [38-40]	0•06
> 37 weeks	21 649 (83•7)	9 273 (83•7)	0•77	7 372 (84•6)	0•16
≥32 and ≤37 weeks	3 633 (14•0)	1 573 (14•2)		1 173 (13•5)	
□ 32 weeks	576 (2•2)	235 (2•1)		164 (1•9)	
<b>Parity, n (%)</b>					
Primiparity	14 759 (57•1)	6 258 (56•5)	0•28	4 698 (53•9)	<0•0001
Multiparity	11 099 (42•9)	4 823 (43•5)		4 011 (46•1)	
<b>Gestation, n (%)</b>					
Single gestation	24 322 (94•1)	10 427 (94•1)	0•89	8 258 (94•8)	0•03
Multiple gestation	1 536 (6•0)	654 (5•9)		451 (5•2)	
<b>Childbirth type, n (%)</b>					
Vaginal birth	20 224(78•2)	8 694(78•5)	0•60	7 233 (83•0)	<0•0001
Caesarean section	5 634 (21•8)	2 387 (21•5)		1 476 (17•0)	
<b>Birth weight (grams), n (%)</b>					
Median (IQR)	3 260 [2 920-3 585]	3 270 [2 920-3 590]	0•54	3 260 [2920-3580]	0•78
Low Z score	464 (1•8)	199 (1•8)	0•70	229 (2•6)	<0•0001
Normal Z score	24 631 (95•2)	10 573 (95•4)		8 336 (95•7)	
Macrosomic Z score	763 (3•0)	309 (2•8)		144 (1•7)	
<b>Year of birth, n (%)</b>					
2014	6 386 (24•7)	2 754 (24•9)	0•03	0 (0)	NA
2015	6 554 (25•3)	2 648 (24•9)		0 (0)	
2016	6 377 (24•7)	2 807 (25•3)		0 (0)	
2017	6 541 (25•3)	2 872 (25•9)		0 (0)	
2018	0 (0)	0 (0)		8 709 (100)	

353 Abbreviations: IQR, interquartile range, NA: Not appropriate for testing

354



355 **Table 2• Multivariate analysis of the risk factors for RSV-associated hospitalisation**  
 356 **during the first 6 months of life and predictive variables**  
 357

Variable	Multivariable analysis			Final Model			Score
	OR	[95% CI]	P value	OR	[95% CI]	P value	OR round up
<b>Sex</b>							
Female		Reference					
Male	1•08	[0•85; 1•30]	0•66				
<b>Month of birth</b>							
February to May		Reference			Reference		<b>0</b>
January, June to August	9•25	[4•75; 20•84]	<0•0001	9•23	[5•10; 23•97]	<0•0001	<b>9</b>
September, December	22•82	[11•78; 51•21]	<0•0001	22•7	[11•75; 51•07]	<0•0001	<b>23</b>
October, November	46•35	[24•40; 102•73]	<0•0001	46•3	[24•41;	<0•0001	<b>46</b>
<b>Gestational age</b>							
>37 weeks		Reference			Reference		<b>0</b>
≥32 and ≤37 weeks	1•64	[1•21; 2•20]	0•00	1•71	[1•29; 2•24]	0•00	<b>2</b>
<32 weeks	3•26	[1•80; 5•52]	<0•0001	3•43	[1•93; 5•68]	<0•0001	<b>3</b>
<b>Parity</b>							
Primiparity		Reference			Reference		<b>0</b>
Multiparity	3•89	[3•07; 4•97]	<0•0001	3•88	[3•06; 4•95]	<0•0001	<b>4</b>
<b>Gestation</b>							
Simple gestation		Reference					
Multiple gestation	1•16	[0•77; 1•70]	0•45				
<b>Birth weight (%)</b>							
Normal Z score		Reference					
Low Z score	1•37	[0•53; 2•87]	0•46				
Macrosomic Z score	1•42	[0•81; 2•30]	0•19				

358 Abbreviations: OR, Odds Ratio; CI, confidence interval; NS, non-significant•

359

360 **Table 3: Characteristics of the low-, moderate-, and high-risk groups according to the**  
 361 **predictive model•**  
 362


	Low Risk Group	Moderate Risk Group	High Risk Group
Risk Factors	Any delivery February to May  and  deliveries in January or June to August with only one other risk factor (prematurity or multiparity)	Deliveries in January or June to August with prematurity and multiparity,  and  deliveries in September or December with only one other risk factor (prematurity or multiparity)	Any delivery in October to November  and  deliveries in September or December with two risk factors (prematurity and multiparity)
Preventive Intervention	Standard	Non Pharmaceutical Intervention Education Program	Non Pharmaceutical Intervention Education Program  And  Pharmaceutical Intervention Maternal Vaccine (term), or Monoclonal antibody (term, preterm)
Population proportion*	53% (4 643/8 709)	32% (2 748/8 709)	15% (1 318/8 709)
Incidence RSVh /1000**	1•72/1000	18•92/1000	46•28/1000

363 \*Calculated on the validating cohort. Incidence of infants hospitalised in the first 6 months of  
 364 life per 1000 infants

365

366 **Figure 1: Flowchart of the study**


367



368

369

370 **Figure 2• Incidence of infants hospitalised during the first six months of life according to**  
371 **month of birth and number of hospitalisations per month in the studied population•**  
372



373

374 Red line: Number of RSVh per month; Black column: Incidence of RSVh in the first 6  
375 months of life per 1000 infants stratified according to month of birth.

376

377

378 **Contributors**

379 MJ, JSC, MB, CH contributed to the literature search, the figures and study design. MJ, JSC,  
380 MB, CH, SCT, AFMD, DP YG, EJ, and BL contributed to data collection, MJ, JSC, MB have  
381 verified the underlying data. All authors, contributed to the data interpretation, critically  
382 reviewed the manuscript, and approved the final manuscript for submission.

383

384 **Declaration of interests**

385 We declare no competing interests.

386

387 **Data Sharing**

388 Aggregated data are available on reasonable request.

389

390 **Acknowledgement**

391 We acknowledge the contribution of the paediatric department, laboratory technical staff, the  
392 BEHcl Team, and Véréna Landel (*Direction de la Recherche en Santé*, HCL – Proof Reading  
393 of the manuscript).

394

395 **References**

- 396 1 Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response.  
397 *Paediatr Respir Rev* 2004; **5 Suppl A**: S119-126.
- 398 2 Hall CB, Weinberg GA, Iwane MK, *et al.* The burden of respiratory syncytial virus  
399 infection in young children. *N Engl J Med* 2009; **360**: 588–98.
- 400 3 Shi T, McAllister DA, O’Brien KL, *et al.* Global, regional, and national disease burden  
401 estimates of acute lower respiratory infections due to respiratory syncytial virus in young  
402 children in 2015: a systematic review and modelling study. *Lancet* 2017; **390**: 946–58.
- 403 4 Deshpande SA, Northern V. The clinical and health economic burden of respiratory  
404 syncytial virus disease among children under 2 years of age in a defined geographical area.  
405 *Arch Dis Child* 2003; **88**: 1065–9.
- 406 5 Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of  
407 hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A  
408 data linkage modelling study. *J Infect* 2019; **78**: 468–75.

- 409 6 Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory  
410 syncytial virus (RSV) infection. *J Pediatr* 2003; **143**: S112-117.
- 411 7 Murray J, Bottle A, Sharland M, *et al.* Risk factors for hospital admission with RSV  
412 bronchiolitis in England: a population-based birth cohort study. *PLoS One* 2014; **9**:  
413 e89186.
- 414 8 Hardelid P, Verfuenden M, McMenamin J, Smyth RL, Gilbert R. The contribution of child,  
415 family and health service factors to respiratory syncytial virus (RSV) hospital admissions  
416 in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Euro Surveill* 2019;  
417 **24**. DOI:10.2807/1560-7917.ES.2019.24.1.1800046.
- 418 9 Bracht M, Basevitz D, Cranis M, Paulley R, Paes B. Strategies for reducing the risk of  
419 respiratory syncytial virus infection in infants and young children: a Canadian nurses'  
420 perspective. *Neonatal Netw* 2012; **31**: 357–68.
- 421 10 Casalegno J-S, Ploin D, Cantais A, *et al.* Characteristics of the delayed respiratory  
422 syncytial virus epidemic, 2020/2021, Rhône Loire, France. *Euro Surveill* 2021; **26**:  
423 2100630.
- 424 11 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of  
425 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections.  
426 *Proc Natl Acad Sci U S A* 2020; **117**: 30547–53.
- 427 12 Meissner HC, Welliver RC, Chartrand SA, *et al.* Immunoprophylaxis with palivizumab, a  
428 humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory  
429 syncytial virus infection in high risk infants: a consensus opinion. *Pediatr Infect Dis J*  
430 1999; **18**: 223–31.
- 431 13 Madhi SA, Polack FP, Piedra PA, *et al.* Respiratory Syncytial Virus Vaccination during  
432 Pregnancy and Effects in Infants. *New England Journal of Medicine* 2020; **383**: 426–39.
- 433 14 Griffin MP, Yuan Y, Takas T, *et al.* Single-Dose Nirsevimab for Prevention of RSV in  
434 Preterm Infants. *New England Journal of Medicine* 2020; **383**: 415–25.
- 435 15 Cody Meissner H. Approaching the End of the Era of Uncontrolled Respiratory Syncytial  
436 Virus Disease. *J Infect Dis* 2021; **223**: 737–9.
- 437 16 Artin B, Pitzer VE, Weinberger DM. Assessment and optimization of respiratory syncytial  
438 virus prophylaxis in Connecticut, 1996-2013. *Sci Rep* 2021; **11**: 10684.
- 439 17 Mazur NI, Higgins D, Nunes MC, *et al.* The respiratory syncytial virus vaccine landscape:  
440 lessons from the graveyard and promising candidates. *Lancet Infect Dis* 2018; **18**: e295–  
441 311.
- 442 18 Kappen TH, Peelen LM. Prediction models: the right tool for the right problem. *Curr Opin*  
443 *Anaesthesiol* 2016; **29**: 717–26.
- 444 19 Simões EAF, Carbonell-Estrany X, Fullarton JR, *et al.* A predictive model for respiratory  
445 syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of  
446 gestational age, based on data from the Spanish FLIP Study. *Respir Res* 2008; **9**: 78.

- 447 20Sampalis JS, Langley J, Carbonell-Estrany X, *et al.* Development and validation of a risk  
448 scoring tool to predict respiratory syncytial virus hospitalization in premature infants born  
449 at 33 through 35 completed weeks of gestation. *Med Decis Making* 2008; **28**: 471–80.
- 450 21Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus  
451 prophylaxis in premature infants born at 33-35 completed weeks' gestational age in  
452 Canada. *Curr Med Res Opin* 2009; **25**: 1585–91.
- 453 22Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV Neonatal  
454 Network. Prospective validation of a prognostic model for respiratory syncytial virus  
455 bronchiolitis in late preterm infants: a multicenter birth cohort study. *PLoS One* 2013; **8**:  
456 e59161.
- 457 23Houben ML, Bont L, Wilbrink B, *et al.* Clinical prediction rule for RSV bronchiolitis in  
458 healthy newborns: prognostic birth cohort study. *Pediatrics* 2011; **127**: 35–41.
- 459 24Kramer R, Duclos A, VRS study group in Lyon, Lina B, Casalegno J-S. Cost and burden of  
460 RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France.  
461 *Vaccine* 2018; **36**: 6591–3.
- 462 25Blencowe H, Cousens S, Oestergaard MZ, *et al.* National, regional, and worldwide  
463 estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected  
464 countries: a systematic analysis and implications. *Lancet* 2012; **379**: 2162–72.
- 465 26Évolution et structure de la population en 2015 – Population en 2015 | Insee.  
466 <https://www.insee.fr/fr/statistiques/3564100?sommaire=3561107> (accessed Feb 2, 2022).
- 467 27Demont C, Petrica N, Bardoulat I, *et al.* Economic and disease burden of RSV-associated  
468 hospitalizations in young children in France, from 2010 through 2018. *BMC Infect Dis*  
469 2021; **21**: 730.
- 470 28Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-  
471 operating characteristic analysis for diagnostic tests. *Prev Vet Med* 2000; **45**: 23–41.
- 472 29Youden WJ. Index for rating diagnostic tests. *Cancer* 1950; **3**: 32–5.
- 473 30CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé mentale  
474 pendant l'épidémie de COVID-19. <https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19> (accessed Feb 2, 2022).
- 477 31Liu D, Leung K, Jit M, Wu JT. Cost-effectiveness of strategies for preventing paediatric  
478 lower respiratory infections associated with respiratory syncytial virus in eight Chinese  
479 cities. *Vaccine* 2021; **39**: 5490–8.
- 480 32Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors  
481 for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.  
482 *Am J Epidemiol* 1991; **133**: 1135–51.
- 483 33Wang X, Li Y, Vazquez Fernandez L, *et al.* Respiratory Syncytial Virus-Associated  
484 Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries.  
485 *J Infect Dis* 2022; : jia560.

- 486 34Rietveld E, Vergouwe Y, Steyerberg EW, *et al.* Hospitalization for respiratory syncytial  
487 virus infection in young children: development of a clinical prediction rule. *Pediatr Infect*  
488 *Dis J* 2006; **25**: 201–7.
- 489 35Rossi GA, Medici MC, Arcangeletti MC, *et al.* Risk factors for severe RSV-induced lower  
490 respiratory tract infection over four consecutive epidemics. *Eur J Pediatr* 2007; **166**: 1267–  
491 72.
- 492 36Papadopoulos NG, Moustaki M, Tsolia M, *et al.* Association of rhinovirus infection with  
493 increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med* 2002; **165**:  
494 1285–9.
- 495 37Biot B, Gillet Y, Casalegno J-S. DETERMINANTS DE LA GRAVITE DES  
496 BRONCHIOLITES A VRS. ANALYSE DES FACTEURS DE RISQUE  
497 SOCIODEMOGRAPHIQUES, VIROLOGIQUES ET ENVIRONNEMENTAUX SUR LA  
498 SAISON 2016-17 A LYON (Frech). 2018; published online June 15.  
499 DOI:10.13140/RG.2.2.19956.48004.
- 500 38Fitzpatrick T, McNally JD, Stukel TA, *et al.* Family and Child Risk Factors for Early-Life  
501 RSV Illness. *Pediatrics* 2021; **147**: e2020029090.

502

503